Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
CorMedix (CRMD) Tops Q2 EPS by 12c, Beats on Revenue
August 7, 2025 7:06 AM EDTCorMedix (NASDAQ: CRMD) reported Q2 EPS of $0.28, $0.12 better than the analyst estimate of $0.16. Revenue for the quarter came in at $39.7 million versus the consensus estimate of $33.06 million.
For earnings history and earnings-related data on CorMedix (CRMD) click here.
... More